Eli Lilly And Company ((LLY)), Abbvie ((ABBV)), Genmab (Otc) ((GMAB)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly And Company, AbbVie, and Genmab are collaborating on a clinical study titled A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome. The study aims to evaluate the safety and efficacy of epcoritamab, a promising antibody treatment, in patients with challenging forms of leukemia and lymphoma, offering potential new therapies for these conditions.
The study tests epcoritamab as a monotherapy and in combination with other drugs like venetoclax, pirtobrutinib, lenalidomide, and R-CHOP. These interventions target relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter’s Syndrome (RS), aiming to improve patient outcomes.
This interventional study is non-randomized with a parallel assignment model and no masking, focusing primarily on treatment. It includes a dose-escalation phase to determine optimal dosing and an expansion phase to assess efficacy and safety.
The study began on November 25, 2020, with a primary completion date set for 2025. The last update was submitted on July 30, 2025, indicating ongoing recruitment and data collection.
For investors, the study’s progress could influence the stock performance of Eli Lilly, AbbVie, and Genmab, as successful outcomes may enhance their market positions in oncology. The competitive landscape in cancer treatment remains intense, with advancements potentially impacting investor sentiment.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.